Celldex Therapeutics: MACD Death Cross, KDJ Death Cross on 15-minute chart.

In accordance with the 15-minute chart of Celldex Therapeutics, a notable trend reversal has been observed, as the MACD Death Cross and KDJ Death Cross indicators have been triggered at 08/13/2025 13:30. This suggests that the stock price may experience a further decline, as the momentum of the stock price is shifting towards a downward trajectory. As such, investors should be cautious and monitor the stock's performance closely.

August 12, 2025 – Celldex Therapeutics (NASDAQ: CLDX) encountered a significant technical setback today as its 15-minute chart triggered an RSI Overbought signal and a KDJ Death Cross at 13:45. This development suggests that the stock price has risen too quickly and is now exceeding fundamental support levels, potentially indicating a shift in momentum towards a decline. Investors should be cautious, as this could signal a further decrease in the stock price.

The RSI Overbought signal indicates that the Relative Strength Index is above 70, suggesting that the stock has been overvalued relative to its historical price movements. The KDJ Death Cross, which occurs when the K line crosses below the D line, is another indicator of a potential reversal in the stock's price trend. These signals collectively suggest that the current upward momentum in CLDX's stock price may be unsustainable.

Despite these technical challenges, Celldex Therapeutics continues to make significant strides in its clinical pipeline. The company's lead drug, barzolvolimab, demonstrated remarkable results in Phase 2 studies for chronic spontaneous urticaria (CSU), with up to 41% of patients maintaining complete response 7 months after treatment completion [1]. Furthermore, the company is advancing its global Phase 3 program in CSU with two trials enrolling approximately 915 patients each, and multiple data readouts are expected in the second half of 2025 [1].

Celldex also presented positive 52-week data from its Phase 2 trial of barzolvolimab at the EAACI 2025 Congress, showing remarkable improvements in angioedema symptoms and clinically meaningful improvements in AAS7 scores at Week 52 [2]. These clinical results highlight the potential of barzolvolimab as a transformative treatment for CSU patients.

However, the technical indicators point to a potential near-term correction in the stock price. Investors should remain vigilant and monitor the company's financial health and clinical progress closely. The company's cash reserves of $630.3 million, sufficient through 2027, and its ongoing R&D expenses of $54.2 million in the second quarter of 2025, provide a solid financial foundation [1].

In summary, while Celldex Therapeutics continues to make promising advancements in its clinical pipeline, the recent technical indicators suggest a potential reversal in the stock's price trend. Investors should approach this situation with caution and consider the broader market conditions and the company's long-term prospects.

References:
[1] https://www.stocktitan.net/news/CLDX/
[2] https://www.stocktitan.net/news/CLDX/